Staurosporine

目录号:S1421 别名: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 2186.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。
靶点
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外研究

Staurosporine 也强抑制HeLa S3细胞,IC50为4 nM。[1]Staurosporine 也抑制多种其他蛋白激酶,包括PKA, PKG, 磷酸激酶, S6 激酶, 肌球蛋白轻链激酶(MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, 和Syk , IC50分别为 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 和 16 nM。[3] Staurosporine (1 μM) 诱导 PC12细胞90%以上凋亡,这种作用可被过量表达的Bcl-2抑制,或者zVAD-fmk, cycloheximide (10 μM) 及actinomycin D (5 μM)处理也可抑制。相应地, Staurosporine处理,诱导细胞内游离钙水平 [Ca2+]i快速且持久的提升,线粒体活性氧(ROS)的积累,及 随后的线粒体功能障碍。[4]通过caspase-8激活和Bid 分裂,功能性caspase-3的表达可增强Staurosporine诱导MCF7细胞死亡。[5] 1 μM Staurosporine处理,只部分抑制IL-3刺激的Bcl2 磷酸化,而完全阻断PKC调节的 Bcl2磷酸化。[6] Staurosporine 诱导人类包皮成纤维细胞AG-1518凋亡,根据溶酶体组织蛋白酶D调节的 细胞色素 c释放和 caspase 激活。[7] 除了激活传统线粒体凋亡通路, Staurosporine触发一种新型内在凋亡通路, 依赖Apaf-1存在时对caspase-9的激活。[8]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MXXDfZRwfG:6aXRCpIF{e2G7 MmPMOFghcA>? NEXJbWZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OIUuODZizszNMi=> MnTCNlE{QDhzOUG=
human colon cancer cell line (LoVo cells) MVXQdo9tcW[ncnH0bY9vKGG|c3H5 NGHMU2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v NHLsVokyOTV7MUWwOS=>
human LoVo cells NFvneZpRem:uaX\ldoF1cW:wIHHzd4F6 MkDvOFghfG9iN{KgbC=> M1XQWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 NFOyfVIzOjF6MkmyPS=>
P19 cells M3LacGZ2dmO2aX;uJIF{e2G7 NVHKWVF3UW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTBwMECyJO69VS5? Ml[1NVU4PzF2MUm=
human BJ cells Mn21R5l1d3SxeHnjxsBie3OjeR?= NUjpNphqPzJiaB?= Mn7KR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OC5yMEKg{txONg>? NWTJeVdSOjJ7MkGwPFE>
human HT-29 cells M3nZ[WZ2dmO2aX;uJIF{e2G7 MX:yJIg> M4rDWGVn\mWldDDvckBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDpckBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjCyJIhzeyC3c3nu[{BLSy1zIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfS=> NWXUXW1bOjF2MkizO|U>
human A549 cells M1\w[2N6fG:2b4jpZ:Kh[XO|YYm= NH;vc2I4OiCq M3\0OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgcYV1cG:m MmjLNVg1QDR5N{W=
human HT-29 cells M1HadGZ2dmO2aX;uJIF{e2G7 NVzuclllUW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCxdHXueIlidCCrbjDoeY1idiCKVD2yPUBk\WyuczD1d4lv\yCMQ{Gg[JlmKHO2YXnubY5oKGK7IH\seY9z\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYYPzZZktKEmFNUC9Nk42KG6P MYGyNVUyOzJ7Mx?=
human HT-29 cells NWLjNXlRTnWwY4Tpc44h[XO|YYm= MlnKNkBp M2HreWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSGStNlkh[2WubIOgZZN{\XO|ZXSgdoVlfWO2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIFnfGW{IEKgbJJ{KGK7IIXzbY5oKEqFMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViY3XscE1j[XOnZDDhd5NigSxiRVO1NF0zNjZibl2u M{nselIyQTd|MUCx
Sf9 cells NGnBdm1HfW6ldHnvckBie3OjeR?= NFL4O3NKdmirYnn0bY9vKG:oIHj1cYFvKFO7azDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVMhdk1w NYGxZ5REOTh6MkO3PFQ>
human HUVEC NWHsbIxvWHKxbHnm[ZJifGmxbjDhd5NigQ>? NYH2XVJkPDhidH:gO|IhcA>? MkWyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7 MXmyNlE5Ojl{OR?=
P19 cells M4jSUWZ2dmO2aX;uJIF{e2G7 NEXiV2NKdmirYnn0bY9vKG:oIGDyc5RmcW5iS3nuZZNmKEFiaX6gVFE6KGOnbHzzMEBKSzVyPUSgcm0v M3vxPFE2PzdzNEG5
Sf9 cells MljKSpVv[3Srb36gZZN{[Xl? NUHBNZhbUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= NH;McIgyPzNzNUi1Ny=>
Sf21 cells MojwSpVv[3Srb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKEqDS{Og[ZhxemW|c3XkJIlvKFOoMkGgZ4VtdHNuIFnDOVA:PiCwTT6= M1\0ZlE4ODh6MEW5
human colon carcinoma cell line HCT116 NIW3VHJHfW6ldHnvckBie3OjeR?= M{TvWGNwdmOnboTyZZRqd25icnXxeYlz\WRiZn;yJIdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKGyrbnWgTGNVOTF4LDDJR|UxRTZibl2u MUexOVU{PzN2NR?=
human ST486 cells MorRVJJwdGmoZYLheIlwdiCjc4PhfS=> NI\UVHU1QCC2bzC3NkBp NWT0ZpR4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWFQ5PiClZXzsd{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdibl2u M{\oNlIzOTh{OUK5
human MDA-MB-231 cells MXXDfZRwfG:6aXRCpIF{e2G7 NFfiS4Y4OiCq M{H5bWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= NHLtfJcyQDR6NEe3OS=>
P19 cells M4XW[GZ2dmO2aX;uJIF{e2G7 MnnNTY5pcWKrdHnvckBw\iCFeXPsbY4u\GWyZX7k[Y51KGurbnHz[UAyKGmwIGCxPUBk\WyuczygTWM2OD16IH7NMi=> MUWxOVc4OTRzOR?=
human DLD1 cells MkTyVJJwdGmoZYLheIlwdiCjc4PhfS=> NFrOOFQ1QC15MjDo MkPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? M4nLdVIzOTh{OUK5
insect cells MlHiSpVv[3Srb36gZZN{[Xl? NFmxUGxKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDpcVEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{BjgSCKVGLGMEBKSzVyPUGwJI5ONg>? MkPyNVkyPzlyN{[=
V79 MZ cells M2\LZ2Z2dmO2aX;uJIF{e2G7 M4GycWlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> MoK5NlQ1OjJ3MUm=
P19 cells NEPpc41HfW6ldHnvckBie3OjeR?= NXjVfIF4UW6qaXLpeIlwdiCxZjDWZZNkfWyjcjDlcoRwfGinbHnhcEBoem:5dHig[oFkfG:{IILlZ4VxfG:{IHnuJHAyQSClZXzsd{whUUN3ME2xOEBvVS5? M2C3e|E2PzdzNEG5
Sf9 cells MkfwSpVv[3Srb36gZZN{[Xl? Ml;KNlAhdWmwcx?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> MUexO|MyPTh3Mx?=
human PBMC MVvGeY5kfGmxbjDhd5NigQ>? M3\mW|I1KGh? M1jqfXN2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?= NGPBOYsyQDV6NUC0Oi=>
human A549 cells MV7DfZRwfG:6aXRCpIF{e2G7 M3HZc|Q5KGh? M3LSSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9NlAhdk1w MUSyOVgzPTl|NB?=
human CEM cells NXi0d2pIS3m2b4TvfIlkyqCjc4PhfS=> NI\zOmY4OiCq NE\FXWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v MUiyNlkzOTB6MR?=
human HeLa cells MVPDfZRwfG:6aXRCpIF{e2G7 NYPWWVBLPDhiaB?= MnSwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUK1JI5ONg>? MVKyOVgzPTl|NB?=
human PC3 cells M2XSbmN6fG:2b4jpZ:Kh[XO|YYm= MlPTOFghcA>? NGjqVWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w MWCyOVgzPTl|NB?=
human SF268 cells NGPOPFZEgXSxdH;4bYPDqGG|c3H5 MlTDOFghcA>? NEHUfGREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVQ1KG6PLh?= M{DaUFIyPTF|Mkm0
human MCF7 cells NX3sO2l6S3m2b4TvfIlkyqCjc4PhfS=> M1v5[FQ5KGh? MmjpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWwJI5ONg>? MlLsNlE{QDhzOUG=
HEK293 cells M1fGSGN6fG:2b4jpZ:Kh[XO|YYm= NVX1V3YzPzJiaB?= MmLBR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XKJbH:gZZN{[XluIFnDOVA:PTZibl2u MnzMNlQ4PjN{NkK=
HUE cells MkjSSpVv[3Srb36gZZN{[Xl? NVKxR5NFQTBibXnudy=> MVfJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCKVVWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emWjdHXkJIZweiB7MDDtbY5{KGKnZn;y[UBXTUeIIHPoZYxt\W6pZTDifUBGVEmVQTygTWM2OD15MDDuUU4> MknqNlAyPzBzNkO=
human A431 cells NFPCPIZEgXSxdH;4bYPDqGG|c3H5 MYmyOEAhcA>? MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEK0JIhzeyC3c3nu[{BCdm6neHnuJHZmTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHL5JG1VXCCjc4PhfUwhUUN3ME23NEBvVS5? M1fae|IzPTRzMEWx
human Jurkat cells M1jjR3Bzd2yrZnXyZZRqd25iYYPzZZk> M1zic2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTmFMOyCneIDy[ZN{cW6pIFnMNk1{fGmvdXzheIVlKGi3bXHuJGp2emujdDDj[YxteyxiSVO1NF04OSCwTT6= MXSxPVQzPzJyMx?=
HEK293 cells MmXDSpVv[3Srb36gZZN{[Xl? MmSxTY5pcWKrdHnvckBw\iCLTD24JJJmdGWjc3WgZpkhUEWNMkmzJINmdGy|IHX4dJJme3OrbnegVGtENWKndHGyMEBKSzVyPUe3JI5ONg>? NETvTVEyPTd5MUSxPS=>
human KE-97 cells NIezSmtEgXSxdH;4bYPDqGG|c3H5 NV;icFRYPzJiaB?= MoLuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2UuQTdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOyEQvF2u NE\yTIczPDN{OEK4Ny=>
human CHOK1 cells M3zjO2N6fG:2b4jpZ:Kh[XO|YYm= MYe0PEBp M{DOOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNJV0tzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjF|IN88UU4> NV6xVVBMOjF3MUOyPVQ>
mouse NIH/3T3 cells NFz1WnBEgXSxdH;4bYPDqGG|c3H5 NUWzdHhyQTZiaB?= NXPXVWVLS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v NXnOWGRsOjR|NkG1NlE>
human A2780 cells NWS5SIJDS3m2b4TvfIlkyqCjc4PhfS=> NV[5W5BtQTZiaB?= M{HzR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= MojsNlQ{PjF3MkG=
human 8505C cells NHHENlJEgXSxdH;4bYPDqGG|c3H5 NGD4PXY6PiCq Ml;wR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= MnTqNlQ{PjF3MkG=
human 518A2 cells MXTDfZRwfG:6aXRCpIF{e2G7 MofvPVYhcA>? NHn6T29EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> NXrXcYc4OjR|NkG1NlE>
human HuH7 cells M1H1fGN6fG:2b4jpZ:Kh[XO|YYm= NWHwdm1HPzJiaB?= NV[5RnFxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> M1z5e|I1OzJ6Mkiz
FL5.12-Akt1 cells NIjue4VRem:uaX\ldoF1cW:wIHHzd4F6 NInPVotCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> NVS1dpVGOTZ2MEO2NlY>
human MiaPaCa-2 cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 M4[zb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXnhVIFE[S1{IHPlcIx{NCCLQ{WwQVAvOzdizszNMi=> MnXpNVY1OTN5OEC=
human BGC823 cells NG\WS5ZEgXSxdH;4bYPDqGG|c3H5 MXW3NkBp MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QCEQvF2u Ml\sNlQ{Ojh{OEO=
human MCF7 cells NWDHXpJxS3m2b4TvfIlkyqCjc4PhfS=> NH;4U4U6PiCq MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? M3\TeVI1OzZzNUKx
human A549 cells NG\O[I9EgXSxdH;4bYPDqGG|c3H5 NUTmNIs4QTZiaB?= M4rLZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlYh|ryPLh?= NX7L[nNQOjR|NkG1NlE>
HEK293 cells MlTBR5l1d3SxeHnjxsBie3OjeR?= NYLyVYtjS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? MkfvNlU{OTZ|MUe=
human Raji cells  NVjINnB1S3m2b4TvfIlkyqCjc4PhfS=> M2TmbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJicmliY3XscJMtKEWFNUC9NkDPxE1w NEnydJAzPTNzNkOxOy=>
human HepG2 cells NIS1NGNEgXSxdH;4bYPDqGG|c3H5 M4jhSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCHQ{WwQVIh|ryPLh?= Mkn5NlU{OTZ|MUe=
human BJ cells M1jGdWN6fG:2b4jpZ:Kh[XO|YYm= M3S2T2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzMEBGSzVyPUKg{txONg>? Mmn6NlU{OTZ|MUe=
human U937 cells M37DU2N6fG:2b4jpZ:Kh[XO|YYm= MlrWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{whUUN3ME2yJO69VS5? MV[xO|A5QDB4Nx?=

... Click to View More Cell Line Experimental Data

体内研究 在局部贫血前,使用Staurosporine(0.1-10 ng)预处理局部贫血沙鼠和大鼠模型,可防止神经元损伤,这种作用存在剂量依赖性,说明CAl锥体细胞死亡涉及PKC。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
细胞实验:[4]
+ 展开
  • Cell lines: PC12
  • Concentrations: 溶于DMSO,终浓度为1 μM
  • Incubation Time: ~32 小时
  • Method: 使用Staurosporine处理细胞32小时。细胞在4%多聚甲醛中混合,然后使用DNA结合染料Hoechst 33342染色。在荧光照明下观察细胞,测定凋亡细胞百分数。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 短暂局部贫血的雄性Mongolian沙鼠或雄性 Wistar大鼠
  • Formulation: 溶于DMSO,然后在盐水中稀释
  • Dosages: ~10 ng
  • Administration: 定向处理到海马双边CA1子域
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 466.53
化学式

C28H26N4O3

CAS号 62996-74-1
稳定性 powder
别名 CGP 41251

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PKC Signaling Pathway Map

相关PKC产品

Tags: 购买Staurosporine | Staurosporine供应商 | 采购Staurosporine | Staurosporine价格 | Staurosporine生产 | 订购Staurosporine | Staurosporine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID